Immunitybio announces execution of $50 million equity financing with multiple institutional investors

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.
IBRX Ratings Summary
IBRX Quant Ranking